Envisagenics

Executive Summary

Envisagenics is a private biotechnology company that leverages its proprietary AI platform, SpliceCore®, to discover and develop RNA splicing-based therapies for oncology and neurodegenerative diseases. By analyzing disease-specific splicing alterations, the platform identifies novel therapeutic targets that would be challenging to find using traditional genomics approaches. Founded in 2014 and headquartered in New York, the company aims to address the significant unmet need in diseases driven by splicing dysregulation. Its AI-driven approach offers the potential for more precise and effective RNA-targeted treatments, positioning it at the forefront of the emerging field of splicing therapeutics. The company has not yet disclosed its development stage or funding history, but the growing interest in RNA-based modalities and AI-driven drug discovery suggests a favorable environment for Envisagenics. Its ability to differentiate from other RNA-focused biotechs depends on the validation of SpliceCore's target predictions in preclinical and, eventually, clinical settings. Key near-term value drivers include potential partnerships with larger pharmaceutical companies seeking novel targets, as well as progression of its internal pipeline toward the clinic. With a focused strategy and a differentiated platform, Envisagenics represents an early-stage opportunity in the precision medicine space, though significant risks remain regarding platform validation, competition, and capital requirements.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership or licensing deal for SpliceCore platform40% success
• Q4 2026Preclinical proof-of-concept data for lead oncology target60% success
• Q2 2026Series B financing round to advance pipeline50% success